Jenny Chang is an Oncology physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6550 Fannin St
Suite 1101
Houston, TX 770302717
Telephone
713-441-0006Registry record last updated 8 Mar 2016.
Clinical trials
- SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Sponsor: The Methodist Hospital Research Institute
- TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Sponsor: The Methodist Hospital Research Institute
- Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Sponsor: Jenny C. Chang, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Genentech USA, Inc.Program year20241 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
9 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:
- Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)
Methodist Hospital Research Institute
FY2026$654,245R01CA284315 - A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)
Methodist Hospital Research Institute
FY2026$367,053U01CA268813 - Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)
Methodist Hospital Research Institute
FY2025$654,245R01CA284315
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”